Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H JACKSON

Showing results (721-730 of 770) with videos related to

Pageof 77
Sort By:
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Nature Communications|January 9, 2016
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myelomaDavid C Johnson, Niels Weinhold, Jonathan S Mitchell, et al.
Molecular Cell|January 9, 2026
IFI16 senses and protects stalled replication forksAmelia Gamble, Thomas A Ward, Otto P G Wheeler, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Scientific Reports|August 14, 2019
In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI TechniquesPanicos Shangaris, Stavros P Loukogeorgakis, Sindhu Subramaniam, et al.
Scientific Reports|December 26, 2019
Publisher Correction: In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI TechniquesPanicos Shangaris, Stavros P Loukogeorgakis, Sindhu Subramaniam, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
The Journal of Infection|September 29, 2024
Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024Peter D Kirwan, Sarah Foulkes, Katie Munro, et al.
Pageof 77

Showing results (721-730 of 770) with videos related to

Sort By:
Pageof 77
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Nature Communications|January 9, 2016
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myelomaDavid C Johnson, Niels Weinhold, Jonathan S Mitchell, et al.
Molecular Cell|January 9, 2026
IFI16 senses and protects stalled replication forksAmelia Gamble, Thomas A Ward, Otto P G Wheeler, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Scientific Reports|August 14, 2019
In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI TechniquesPanicos Shangaris, Stavros P Loukogeorgakis, Sindhu Subramaniam, et al.
Scientific Reports|December 26, 2019
Publisher Correction: In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI TechniquesPanicos Shangaris, Stavros P Loukogeorgakis, Sindhu Subramaniam, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
The Journal of Infection|September 29, 2024
Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024Peter D Kirwan, Sarah Foulkes, Katie Munro, et al.
Pageof 77